<DOC>
	<DOCNO>NCT02641392</DOCNO>
	<brief_summary>This Phase 3 , double-blind , active treatment extension study evaluate long-term safety GED-0301 208 week subject Crohn 's disease ( CD ) previously participate either follow two Phase 3 GED-0301 study : - Study GED-0301-CD-002 - Study GED-0301-CD-003</brief_summary>
	<brief_title>A Long-term Active Treatment Study Mongersen ( GED-0301 ) Subjects With Crohn 's Disease</brief_title>
	<detailed_description>This long-term active treatment study patient Crohn 's disease ( CD ) . Subjects meet early escape criterion Study GED-0301-CD-002 , subject complete Study GED-0301-002 GED-0301-003 , may eligible study . The duration treatment 208 week consist 3 period : - Screening Period - 4 week - Long-term Active Treatment Period - 208 Weeks ( Week 0 Week 208 ) - Follow-up Period - 4 week ( ie , Investigational product ( IP ) take ) The primary objective ass long-term safety GED 0301 . Additional efficacy patient report outcomes explore .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must satisfy follow criterion screen enrol study : Male female ≥ 18 year age . Subject must participate GED0301CD002 GED 0301 CD 003 study . Subject must use protocol approve contraception . The presence follow exclude subject screen enrollment : Subject experience serious adverse event ( SAE ) relate investigational product participate previous Phase 3 GED0301 study . Subject initiate biologic agent , TNFα blocker integrin antagonist . Subject pregnant breastfeeding . Subject develop know hypersensitivity oligonucleotides , GED 0301 ingredient investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>GED 0301</keyword>
	<keyword>Mongersen</keyword>
	<keyword>Safety</keyword>
	<keyword>IBD</keyword>
</DOC>